SCHEMBL13660645

SCHEMBL13660645

NCCNc1ncccc1N=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PRKCH P24723 2/20 0.41
PRKCE Q02156 2/20 0.41
MAPT P10636 5/20 0.39
FERMT2 Q96AC1 1/20 0.37
SYK P43405 8/20 0.37
PRKCI P41743 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
XBP1 P17861 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CHEK1 O14757 1/20 0.35
CHEK2 O96017 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744803 0.83 KDM4E (0.41) KDM4EALDH1A1HPGDHSD17B10PRKCH
SCHEMBL13660640 0.80 KAT2B (0.50) KDM4EALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL12189388 0.79 GRM5 (0.40) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL7360763 0.75 PRKCH (0.48) KDM4EALDH1A1HPGDHSD17B10PRKCH
SCHEMBL8345840 0.74 L3MBTL1 (0.50) KDM4EALDH1A1HPGDHSD17B10PRKCH
SCHEMBL317634 0.74 PRKCH (0.43) KDM4EALDH1A1HPGDHSD17B10PRKCH
SCHEMBL13931357 0.74 SYK (0.46) KDM4EALDH1A1HPGDHSD17B10PRKCH
SCHEMBL8131156 0.74 PRKCH (0.43) KDM4EALDH1A1HPGDHSD17B10PRKCH
Hydrochloric Acid SCHEMBL28301442 0.72 PRKCH (0.43) KDM4EALDH1A1HPGDHSD17B10PRKCH
SCHEMBL1744805 0.71 ALDH1A1 (0.42) KDM4EALDH1A1HPGDHSD17B10PRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11529350-B2 Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof SUMITOMO PHARMA ONCOLOGY, INC. (US) 2022-12-20 US disclosed
US-20210000825-A1 Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof SUMITOMO PHARMA ONCOLOGY, INC. 2021-01-07 US disclosed
US-7608717-B2 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-10-27 US disclosed
US-20080070943-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210000825-A1 Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof TNK1, TNNI3K, TYK2 KDM4E 1962/4885ALDH1A1 4213/4885HPGD 3496/4885
US-11529350-B2 Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof TNK1, TNNI3K, TYK2 KDM4E 1962/4885ALDH1A1 4213/4885HPGD 3496/4885
US-20080070943-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2C KDM4E 2278/4885ALDH1A1 1019/4885HPGD 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.